Q² Solutions Expands Genomics Capabilities in China

Morrisville, N.C. – July 23, 2018 – Q2 Solutions proudly announces expanded genomics capabilities in China, leveraging more than 16 years of complex genomic testing experience, in addition to providing access to a global network of specialists. Q2 Solutions first began offering Next Generation Sequencing (NGS) solutions at their Beijing facility in 2017, and are continuing to expand their test menu and technology investments to meet market needs in China. These resources have been further augmented by a team of bilingual scientific experts, including bioinformaticians, pathologists, and medical technologists. This aids in effective communication while supporting the entire clinical trial continuum, from early discovery through Companion Diagnostic development.

Q2 Solutions is a global, full-service, platform agnostic clinical trials laboratory services organization offering scalable genomic solutions, in China, for NGS, inclusive of targeted sequencing, exome sequencing, RNA sequencing, and Whole Human Genome sequencing. Cutting-edge genomics tools facilitate the characterization of challenging samples including Formalin-Fixed Paraffin-Embedded (FFPE) and whole blood. Central Laboratory solutions provide an extensive array of services and esoteric specialty tests, which enhance biomarker discovery through a multi-dimensional approach. Combining NGS with onsite anatomical pathologists to support individual study needs, these resources are imperative to successfully uncovering relationships between genes, mutations, and disease. Additionally, our in-house developed and validated world-class bioinformatics pipelines ensure big data sets are translated into actionable insights.

“Genomics technologies can help streamline clinical trial enrollment by identifying patients who may be more likely to benefit from a therapy, which can lead to a stronger regulatory submission package. I am extremely pleased about the expansion of our genomics capabilities in China. Our enhanced ability to support the China market and the global drug development needs of our customers around the world is critical in this ever-changing global regulatory landscape,” said Kellie Yarnell, VP of Q2 Solutions, Genomics Laboratory.

Our facility in Beijing can take projects from the discovery process to full clinical trial implementation, including assay development which is accompanied by efficient project management. Global scalability is possible through harmonized workflows and procedures to ensure reproducibility during clinical trials. Every aspect of a study is monitored, beginning with the in-house biorepository and strict maintenance of sample integrity throughout the life of the study. Since 2011 we have helped more than 42% of breakthrough products through the FDA approval process making us a partner our clients can trust.

Our Beijing laboratory was the first in China to achieve College of American Pathologists (CAP) ISO 15189 accreditation. The site passed a Food and Drug Administration (FDA) inspection in March 2016 without any findings and CFDI has inspected our facility more than 50 times since September 2016.

Download our factsheet to learn more about our full set of central laboratory services in China which support a broad spectrum of development needs, delivering excellence to help ensure high-quality data is generated for regulatory approval in China and beyond.

About Q2 Solutions

Launched in 2015, Q2 Solutions is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q2 Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q2 Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities. To learn more, visit